Chi-Med announced that it has submitted an application for the marketing of a new drug in the US for the treatment of MET-driven EGFR mutant lung cancer in combination with Teresa.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.